Ratings by Wedbush (Yun Zhong)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/2/2026 | Rezolute | RZLT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Kalaris | KLRS | New Coverage | Outperform (N/A) |
4.83 (4.44) |
-8.07% | Details | |
| 4/21/2026 | Passage Bio Inc. | PASG | Downgrade | Neutral (Outperform) |
6.25 (4.57) |
-26.88% | Details | |
| 3/27/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Rezolute | RZLT | Upgrade | Outperform (Neutral) |
2.69 (4.75) |
76.58% | Details | |
| 3/12/2026 | Opus Genetics | IRD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2025 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2025 | Rezolute | RZLT | Downgrade | Neutral (Outperform) |
10.94 (2.69) |
-75.41% | Details | |
| 11/10/2025 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2025 | Opus Genetics | IRD | New Coverage | Outperform (N/A) |
1.93 (3.92) |
103.11% | Details | |
| 10/28/2025 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Passage Bio Inc. | PASG | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2025 | Sagimet Biosciences Inc | SGMT | New Coverage | Outperform (N/A) |
8.73 (7.37) |
-15.58% | Details | |
| 5/27/2025 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Outperform (N/A) |
2.00 (4.33) |
116.5% | Details | |
| 5/13/2025 | Passage Bio Inc. | PASG | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/10/2025 | MannKind | MNKD | New Coverage | Outperform (N/A) |
5.63 (4.09) |
-27.35% | Details | |
| 1/17/2025 | Keros Therapeutics | KROS | Downgrade | Neutral (Outperform) |
10.52 (11.80) |
12.17% | Details | |
| 12/30/2024 | Rocket Pharmaceuticals | RCKT | New Coverage | Outperform (N/A) |
11.75 (3.91) |
-66.72% | Details | |
| 11/29/2024 | Voyager Therapeutics | VYGR | New Coverage | Outperform (N/A) |
5.78 (3.44) |
-40.48% | Details | |
| 11/29/2024 | Passage Bio Inc. | PASG | New Coverage | Outperform (N/A) |
0.67 (6.25) |
832.84% | Details | |
| 11/5/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Outperform (N/A) |
46.76 (20.36) |
-56.46% | Details | |
| 11/5/2024 | Rezolute | RZLT | New Coverage | Outperform (N/A) |
5.50 (10.94) |
98.91% | Details | |
| 11/5/2024 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
125.28 (270.45) |
115.88% | Details | |
| 11/5/2024 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
46.76 (131.42) |
181.05% | Details | |
| 11/5/2024 | Keros Therapeutics | KROS | New Coverage | Outperform (N/A) |
59.94 (11.80) |
-80.31% | Details | |
| 11/5/2024 | BioMarin Pharmaceutical Inc. | BMRN | Upgrade | Outperform (Neutral) |
66.60 (59.12) |
-11.23% | Details |
